Prognostic significance of deregulated dicer expression in breast cancer

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Caffrey, Emer ^a   Ingoldsby, Helen ^a   Wall, Deirdre ^a   Webber, Mark ^a   Dinneen, Kate ^a   Murillo, Laura S ^a   Inderhaug, Celine ^a   Newell, John ^a   Gupta, Sanjeev ^a   Callagy, Grace ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; RIBONUCLEASE III; TUMOR MARKERS, BIOLOGICAL;

EID: 84893522308     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083724     Document Type: Article

References (70)

1. Bartel DP (2004) MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 116: 281-297.
2. Beezhold KJ, Castranova V, Chen F (2010) Microprocessor of microRNAs: regulation and potential for therapeutic intervention. Mol Cancer 9: 134.
3. Yi R, Qin Y, Macara IG, Cullen BR (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17: 3011-3016. (Pubitemid 38040764)
4. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R (2005) Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123: 631-640. (Pubitemid 41608466)
5. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, et al. (2011) MicroRNA sequence and expression analysis in breast tumours by deep sequencing. Cancer Res 71: 4443-4453.
6. Bushati N, Cohen SM (2007) microRNA functions. Annu Rev Cell Dev Biol 23: 175-205.
7. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA processing enhances cellular transformation and tumourigenesis. Nat Genet 39: 673-677. (Pubitemid 46676103)
8. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, et al. (2010) A Genetic Defect in Exportin-5 Traps Precursor MicroRNAs in the Nucleus of Cancer Cells. Cancer Cell 18: 303-315.
9. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, et al. (2009) A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 41: 365-370.
10. Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, et al. (2011) DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 48: 273-278.
11. Hill DA, Ivanovich J, Priest JR, Gurnett CA, Dehner LP, et al. (2009) DICER1 mutations in familial pleuropulmonary blastoma. Science 325: 965.
12. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, et al. (2009) Dicer1 functions as a haploinsufficient tumour suppressor. Genes Dev 23: 2700-2704.
13. Lambertz I, Nittner D, Mestdagh P, Denecker G, Vandesompele J, et al. (2010) Monoallelic but not biallelic loss of Dicer1 promotes tumourigenesis in vivo. Cell Death Differ 17: 633-641.
14. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype. Genome Biol 8: R214.
15. Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, et al. (2009) Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer 101: 673-683.
16. Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, et al. (2011) Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 47: 138-150.
17. Khoshnaw SM, Rakha EA, Abdel-Fatah TM, Nolan CC, Hodi Z, et al. (2012) Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast Cancer Res Treat 135: 403-413.
18. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, et al. (2010) A MicroRNA Targeting Dicer for Metastasis Control. Cell 141: 1195-1207.
19. Passon N, Gerometta A, Puppin C, Lavarone E, Puglisi F, et al. (2012) Expression of Dicer and Drosha in triple-negative breast cancer. J Clin Pathol 65: 320-326.
20. Yan M, Huang H-Y, Wang T, Wan Y, Cui S-D, et al. (2012) Dysregulated Expression of Dicer and Drosha in Breast Cancer. Pathology & Oncology Research 18: 343-348.
21. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 4: 844-847. (Pubitemid 28331029)
22. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
23. (January 2005) NHSBSP Publication No. 58 Pathology Reporting of Breast Disease. NHS Cancer Screening Programmes and The Royal College of Pathologists.
24. Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, et al. (2006) Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98: 1571-1581. (Pubitemid 44680908)
25. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, et al. (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25: 3846-3852. (Pubitemid 47477259)
26. Dowsett M, Allred C, Knox J, Quinn E, Salter J, et al. (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26: 1059-1065.
27. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, et al. (2008) Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 26: 1404-1410.
28. Le MG, Mathieu MC, Douc-Rasy S, Le Bihan ML, Adb El All H, et al. (1999) c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer 84: 562-567.
29. Osanai T, Takagi Y, Toriya Y, Nakagawa T, Aruga T, et al. (2005) Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer. Jpn J Clin Oncol 35: 121-125. (Pubitemid 40514540)
30. Moran MS, Yang Q, Haffty BG (2009) The Yale University Experience of Early-Stage Invasive Lobular Carcinoma (ILC) and Invasive Ductal Carcinoma (IDC) Treated with Breast Conservation Treatment (BCT): Analysis of Clinical-Pathologic Features, Long-Term Outcomes, and Molecular Expression of COX-2, Bcl-2, and p53 as a Function of Histology. The Breast Journal 15: 571-578.
31. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, et al. (1993) Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926-3931. (Pubitemid 23172971)
32. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG (1996) Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2: 585-592. (Pubitemid 26099178)
33. Tan P, Cady B, Wanner M, Worland P, Cukor B, et al. (1997) The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57: 1259-1263. (Pubitemid 27152548)
34. Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, et al. (1999) Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 80: 419-426. (Pubitemid 29213195)
35. Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, et al. (2002) Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 94: 2151-2159. (Pubitemid 34411971)
36. Jansen RL, Hupperets PS, Arends JW, Joosten-Achjanie SR, Volovics A, et al. (1998) MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78: 460-465. (Pubitemid 28360632)
37. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43. (Pubitemid 46174133)
38. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, et al. (1994) The Bcl-2 Protein: a Prognostic Indicator Strongly Related to p53 Protein in Lymph Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute 86: 499-504. (Pubitemid 24111005)
39. Elledge RM, Green S, Howes L, Clark GM, Berardo M, et al. (1997) bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Journal of Clinical Oncology 15: 1916-1922. (Pubitemid 27209521)
40. Ménard S, Casalini P, Tomasic G, Pilotti S, Cascinelli N, et al. (1999) Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Research and Treatment 55: 167-175.
41. Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, et al. (2006) Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 169: 1812-1820. (Pubitemid 351182010)
42. Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, et al. (2008) Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol 21: 676-684. (Pubitemid 351744832)
43. Tchernitsa O, Kasajima A, Schafer R, Kuban RJ, Ungethum U, et al. (2010) Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol 222: 310-319.
44. Faber C, Horst D, Hlubek F, Kirchner T (2011) Overexpression of Dicer predicts poor survival in colorectal cancer. Eur J Cancer 47: 1414-1419.
45. Ma Z, Swede H, Cassarino D, Fleming E, Fire A, et al. (2011) Up-Regulated Dicer Expression in Patients with Cutaneous Melanoma. PLoS ONE 6: e20494.
46. Papachristou DJ, Rao UN, Korpetinou A, Giannopoulou E, Sklirou E, et al. (2012) Prognostic significance of Dicer cellular levels in soft tissue sarcomas. Cancer Invest 30: 172-179.
47. Guo X, Liao Q, Chen P, Li X, Xiong W, et al. (2012) The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma. J Cancer Res Clin Oncol 138: 49-56.
48. Shu GS, Yang ZL, Liu DC (2012) Immunohistochemical study of Dicer and Drosha expression in the benign and malignant lesions of gallbladder and their clinicopathological significances. Pathol Res Pract 208: 392-397.
49. Faggad A, Kasajima A, Weichert W, Stenzinger A, Elwali NE, et al. (2012) Down-regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer. Histopathology.
50. Faggad A, Budczies J, Tchernitsa O, Darb-Esfahani S, Sehouli J, et al. (2010) Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol 220: 382-391.
51. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301. (Pubitemid 44799747)
52. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-964.
53. Cheng C, Fu X, Alves P, Gerstein M (2009) mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol 10: R90.
54. Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, et al. (2007) Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 67: 2345-2350. (Pubitemid 46424256)
55. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, et al. (2005) Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 96: 111-115. (Pubitemid 40425386)
56. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359: 2641-2650.
57. Vaksman O, Hetland TE, Trope CG, Reich R, Davidson B (2012) Argonaute, Dicer, and Drosha are up-regulated along tumour progression in serous ovarian carcinoma. Human pathology.
58. Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, et al. (2006) RNASEN Regulates Cell Proliferation and Affects Survival in Esophageal Cancer Patients. Clinical Cancer Research 12: 7322-7328. (Pubitemid 46095404)
59. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541. (Pubitemid 44854748)
60. Noh H, Hong S, Dong Z, Pan ZK, Jing Q, et al. (2011) Impaired MicroRNA Processing Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen Activator Expression. Genes Cancer 2: 140-150.
61. Bu Y, Lu C, Bian C, Wang J, Li J, et al. (2009) Knockdown of Dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin. Oncol Rep 21: 13-17.
62. Hinkal GW, Grelier G, Puisieux A, Moyret-Lalle C (2011) Complexity in the regulation of Dicer expression: Dicer variant proteins are differentially expressed in epithelial and mesenchymal breast cancer cells and decreased during EMT. Br J Cancer 104: 387-388.
63. Emmerth S, Schober H, Gaidatzis D, Roloff T, Jacobeit K, et al. (2010) Nuclear retention of fission yeast dicer is a prerequisite for RNAi-mediated heterochromatin assembly. Dev Cell 18: 102-113.
64. Sinkkonen L, Hugenschmidt T, Filipowicz W, Svoboda P (2010) Dicer is associated with ribosomal DNA chromatin in mammalian cells. PLoS ONE 5: e12175.
65. Chiosea SI, Barnes EL, Lai SY, Egloff AM, Sargent RL, et al. (2008) Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of Dicer expression. Virchows Arch 452: 629-635.
66. Papachristou DJ, Sklirou E, Corradi D, Grassani C, Kontogeorgakos V, et al. (2012) Immunohistochemical analysis of the endoribonucleases Drosha, Dicer and Ago2 in smooth muscle tumours of soft tissues. Histopathology 60: E28-36.
67. Zheng ZH, Sun XJ, Fu WN, Guan Y, Gao F, et al. (2007) Decreased expression of DICER1 in gastric cancer. Chin Med J (Engl) 120: 2099-2104. (Pubitemid 350268157)
68. Stratmann J, Wang CJ, Gnosa S, Wallin A, Hinselwood D, et al. (2011) Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients. BMC Cancer 11: 345.
69. Cochrane D, Cittelly D, Howe E, Spoelstra N, McKinsey E, et al. (2010) MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer. Hormones and Cancer 1: 306-319.
70. Cancer IUA (2009) TNM Classification of Malignant Tumours, 7th ed. In: Sobin LH GM, Wittekind C editor. Oxford: Wiley-Blackwell.